Replies to post #8523 on Mast Therapeutics, Inc. (MSTX)

[velvet172]

ANX MARKET CAPITALIZATION


If we take a look at ANX and it's competitors, we can get an idea of where this stock could go on success of ANX-530 and ANX-514.

ANX currently has a $43 Million dollar market cap on 14,702,055 shares outstanding (at the current price of $2.92).

HSGI currently has a $4.65 BILLION dollar market cap on 188,794,153 shares outstanding (at the current price of $24.64).

DNDN currently has a $5.4 BILLION dollar market cap on 143,160,127 shares outstanding (at the current price of $37.72).

This is the beauty of what the R/S did for the Company in the LONG RUN. With only 14 Million shares outstanding in this Company, with success of the drugs, this stock could easily run into the $50, $75 and $100 levels VERY quickly.

ANX, at $100/share, would value the market cap at $1.47BILLION (with the current shares outstanding). That is ONLY 27% of the size of DNDN and 32% of the size of HGSI!!

Do you see how much room for growth there is in this Company (assuming success of their drugs)?

The R/S was definitely a negative in the short term, but, in the long term, this had to be done and can greatly reward the investors that stuck with the Company. The potential growth is almost unimaginable!

Do you want to be on the sidelines for this kind of potential?